Free Trial
→ Is the SpaceX IPO “Rigged?” (From The Oxford Club) (Ad)tc pixel Free MRK Stock Alerts

Merck & Co., Inc. (MRK) Financials

Merck & Co., Inc. logo
$113.53 +0.38 (+0.33%)
Closing price 03:59 PM Eastern
Extended Trading
$113.96 +0.43 (+0.38%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Merck & Co., Inc.

Annual Income Statements for Merck & Co., Inc.

This table shows Merck & Co., Inc.'s income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 4,442 3,920 2,394 6,220 9,843 7,067 13,036 14,519 365 17,117 18,254
Consolidated Net Income / (Loss)		 4,459 3,941 2,418 6,193 9,759 7,071 13,049 14,526 377 17,133 18,263
Net Income / (Loss) Continuing Operations		 4,459 3,941 2,418 6,193 5,606 4,523 12,358 14,526 377 17,133 18,263
Total Pre-Tax Income 		5,401 4,659 6,521 8,701 7,171 5,863 13,879 16,444 1,889 19,936 21,067
Total Operating Income		 6,928 4,848 6,021 8,299 7,300 4,973 12,538 17,945 2,355 19,912 21,218
Total Gross Profit		 24,564 25,777 27,210 28,785 27,105 27,900 35,078 41,872 43,989 48,975 48,629
Total Revenue		 39,498 39,807 40,122 42,294 39,121 41,518 48,704 59,283 60,115 64,168 65,011
Operating Revenue		 39,498 39,807 40,122 42,294 39,121 41,518 48,704 59,283 60,115 64,168 65,011
Total Cost of Revenue		 14,934 14,030 12,912 13,509 12,016 13,618 13,626 17,411 16,126 15,193 16,382
Operating Cost of Revenue		 14,934 14,030 12,912 13,509 12,016 13,618 13,626 17,411 16,126 15,193 16,382
Total Operating Expenses		 17,636 20,929 21,189 20,486 19,805 22,927 22,540 23,927 41,634 29,063 27,411
Selling, General & Admin Expense		 10,313 10,017 10,074 10,102 9,455 8,955 9,634 10,042 10,504 10,816 10,733
Research & Development Expense		 6,704 10,261 10,339 9,752 9,724 13,397 12,245 13,548 30,531 17,938 15,789
Restructuring Charge		 619 651 776 632 626 575 661 337 599 309 889
Total Other Income / (Expense), net		 -1,527 -189 500 402 -129 890 1,341 -1,501 -466 24 -151
Other Income / (Expense), net		 -1,527 -189 500 402 -129 890 1,341 -1,501 -466 24 -151
Income Tax Expense		 942 718 4,103 2,508 1,565 1,340 1,521 1,918 1,512 2,803 2,804
Net Income / (Loss) Attributable to Noncontrolling Interest		 17 21 24 -27 -84 4.00 13 7.00 12 16 9.00
Basic Earnings per Share		 $1.58 $1.42 $0.88 $2.34 $3.84 $2.79 $5.16 $5.73 $0.14 $6.76 $7.30
Weighted Average Basic Shares Outstanding		 2.78B 2.77B 2.73B 2.66B 2.54B 2.53B 2.53B 2.54B 2.53B 2.53B 2.47B
Diluted Earnings per Share		 $1.56 $1.41 $0.87 $2.32 $3.81 $2.78 $5.14 $5.71 $0.14 $6.74 $7.28
Weighted Average Diluted Shares Outstanding		 2.78B 2.77B 2.73B 2.66B 2.54B 2.53B 2.53B 2.54B 2.53B 2.53B 2.47B
Weighted Average Basic & Diluted Shares Outstanding		 2.78B 2.77B 2.73B 2.66B 2.54B 2.53B 2.53B 2.54B 2.53B 2.53B 2.47B
Cash Dividends to Common per Share		 $1.81 $1.85 $1.89 $1.99 $2.26 $2.48 $2.64 $2.80 $2.96 $3.12 $3.28

Quarterly Income Statements for Merck & Co., Inc.

This table shows Merck & Co., Inc.'s income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -5,975 4,745 -1,226 4,762 5,455 3,157 3,743 5,079 4,427 5,785 2,963
Consolidated Net Income / (Loss)		 -5,972 4,750 -1,226 4,767 5,461 3,161 3,744 5,085 4,428 5,787 2,963
Net Income / (Loss) Continuing Operations		 -5,972 4,750 -1,226 4,767 5,461 3,161 3,744 5,085 4,428 5,787 2,963
Total Pre-Tax Income 		-5,335 5,620 -2,046 5,670 6,006 4,090 4,170 5,903 4,999 6,745 3,420
Total Operating Income		 -5,163 5,746 -1,967 5,637 6,048 3,928 4,299 5,868 4,992 6,507 3,851
Total Gross Profit		 11,011 11,698 10,719 12,235 12,367 12,577 11,796 12,110 12,249 13,421 10,849
Total Revenue		 15,035 15,962 14,631 15,775 16,112 16,657 15,624 15,529 15,806 17,276 16,400
Operating Revenue		 15,035 15,962 14,631 15,775 16,112 16,657 15,624 15,529 15,806 17,276 16,400
Total Cost of Revenue		 4,024 4,264 3,912 3,540 3,745 4,080 3,828 3,419 3,557 3,855 5,551
Operating Cost of Revenue		 4,024 4,264 3,912 3,540 3,745 4,080 3,828 3,419 3,557 3,855 5,551
Total Operating Expenses		 16,174 5,952 12,686 6,598 6,319 8,649 7,497 6,242 7,257 6,914 6,998
Selling, General & Admin Expense		 2,702 2,519 2,804 2,483 2,739 2,731 2,863 2,552 2,649 2,633 2,899
Research & Development Expense		 13,321 3,307 9,627 3,992 3,500 5,862 4,584 3,621 4,048 4,234 3,886
Restructuring Charge		 151 126 255 123 80 56 50 69 560 47 213
Total Other Income / (Expense), net		 -172 -126 -79 33 -42 162 -129 35 7.00 238 -431
Other Income / (Expense), net		 -172 -126 -79 33 -42 162 -129 35 7.00 238 -431
Income Tax Expense		 637 870 -820 903 545 929 426 818 571 958 457
Basic Earnings per Share		 ($2.35) $1.87 ($0.49) $1.88 $2.15 $1.25 $1.48 $2.01 $1.76 $2.32 $1.21
Weighted Average Basic Shares Outstanding		 2.54B 2.53B 2.53B 2.53B 2.53B 2.53B 2.53B 2.51B 2.50B 2.48B 2.47B
Diluted Earnings per Share		 ($2.35) $1.86 ($0.48) $1.87 $2.14 $1.24 $1.49 $2.01 $1.76 $2.32 $1.19
Weighted Average Diluted Shares Outstanding		 2.54B 2.53B 2.53B 2.53B 2.53B 2.53B 2.53B 2.51B 2.50B 2.48B 2.47B
Weighted Average Basic & Diluted Shares Outstanding		 2.54B 2.53B 2.53B 2.53B 2.53B 2.53B 2.53B 2.51B 2.50B 2.48B 2.47B

Annual Cash Flow Statements for Merck & Co., Inc.

This table details how cash moves in and out of Merck & Co., Inc.'s business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1,083 -2,009 -876 2,076 1,967 -1,769 14 4,606 -5,864 6,409 1,372
Net Cash From Operating Activities		 12,538 10,376 6,451 10,922 8,884 7,617 13,122 19,095 13,006 21,468 16,472
Net Cash From Continuing Operating Activities		 12,538 10,376 6,451 10,922 8,884 7,617 13,122 19,095 13,006 21,468 16,472
Net Income / (Loss) Continuing Operations		 4,459 3,941 2,418 6,193 5,606 4,523 12,358 14,526 377 17,133 18,263
Consolidated Net Income / (Loss)		 4,459 3,941 2,418 6,193 - 4,523 12,358 14,526 377 17,133 18,263
Depreciation Expense		 6,375 5,471 4,676 1,416 1,615 1,669 1,578 1,824 1,828 2,104 3,045
Amortization Expense		 - - - 3,103 1,695 1,817 1,636 2,085 2,044 2,395 2,793
Non-Cash Adjustments To Reconcile Net Income		 2,736 5,086 1,648 2,272 2,605 4,775 1,202 5,010 12,861 4,752 1,018
Changes in Operating Assets and Liabilities, net		 -1,032 -4,122 -2,291 -2,062 -2,637 -5,167 -3,652 -4,350 -4,104 -4,916 -8,647
Net Cash From Investing Activities		 -4,758 -3,210 2,679 4,314 -2,529 -9,193 -16,421 -4,960 -14,083 -7,734 -13,741
Net Cash From Continuing Investing Activities		 -4,758 -3,210 2,679 4,314 -2,529 -9,193 -16,421 -4,960 -14,083 -7,734 -13,741
Purchase of Property, Plant & Equipment		 -1,283 -1,614 -1,888 -2,615 -3,369 -4,429 -4,448 -4,388 -3,863 -3,372 -4,112
Acquisitions		 -7,744 -780 -396 -431 -4,954 -6,606 -12,907 0.00 -12,032 -3,393 -10,042
Purchase of Investments		 -16,681 -15,651 -10,739 -7,994 -3,202 -95 -1.00 -1,204 -955 -519 -1,207
Sale and/or Maturity of Investments		 20,413 14,353 15,664 15,252 8,622 2,812 1,026 721 1,658 377 1,678
Other Investing Activities, net		 221 482 38 102 374 -875 -91 -89 1,109 -827 -58
Net Cash From Financing Activities		 -5,387 -9,044 -10,006 -13,160 -8,861 -2,832 3,097 -9,119 -4,810 -7,032 -1,922
Net Cash From Continuing Financing Activities		 -5,387 -9,044 -10,006 -13,160 -8,861 -2,832 3,097 -9,119 -4,810 -7,032 -1,922
Repayment of Debt		 -4,507 -2,504 -1,324 -4,612 -3,705 156 -6,591 -2,491 -2,083 -1,662 -2,634
Repurchase of Common Equity		 -4,186 -3,434 -4,014 -9,091 -4,780 -1,281 -840 0.00 -1,346 -1,306 -5,084
Payment of Dividends		 -5,117 -5,124 -5,167 -5,172 -5,695 -6,215 -6,610 -7,012 -7,445 -7,840 -8,176
Issuance of Debt		 7,938 1,079 0.00 5,124 4,958 4,419 7,936 0.00 5,939 3,599 13,880
Other Financing Activities, net		 485 939 499 591 361 89 9,202 384 125 177 92
Effect of Exchange Rate Changes		 -1,310 - - - 17 253 -133 -410 - - 563

Quarterly Cash Flow Statements for Merck & Co., Inc.

This table details how cash moves in and out of Merck & Co., Inc.'s business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Net Change in Cash & Equivalents		 -4,074 2,957 -1,760 -1,238 5,702 3,315 -1,370 -4,586 -659 10,187 -3,570
Net Cash From Operating Activities		 3,704 7,717 246 3,090 5,637 9,291 3,450 2,500 3,293 7,822 2,857
Net Cash From Continuing Operating Activities		 3,704 7,717 246 3,090 5,637 9,291 3,450 2,500 3,293 7,822 2,857
Net Income / (Loss) Continuing Operations		 -5,972 4,750 -1,226 4,767 5,461 3,161 3,744 5,085 4,429 5,787 2,962
Consolidated Net Income / (Loss)		 -5,972 4,750 -1,226 4,767 5,461 3,161 3,744 5,085 4,429 5,787 2,962
Depreciation Expense		 426 452 502 511 518 553 522 502 518 532 1,493
Amortization Expense		 477 562 462 473 614 633 675 597 601 622 973
Non-Cash Adjustments To Reconcile Net Income		 10,764 112 1,295 772 237 2,763 980 214 452 -221 573
Changes in Operating Assets and Liabilities, net		 -1,991 1,841 -787 -3,433 -1,193 2,181 -2,471 -3,898 -2,707 1,102 -3,144
Net Cash From Investing Activities		 -11,443 -334 53 -1,376 -1,069 -3,845 -1,444 -1,487 -770 -283 -11,201
Net Cash From Continuing Investing Activities		 -11,443 -334 53 -1,376 -1,069 -3,845 -1,444 -1,487 -770 -283 -11,201
Purchase of Property, Plant & Equipment		 -965 -902 -989 -861 -791 -783 -937 -1,328 -764 -987 -1,033
Acquisitions		 -10,705 - - -746 - -2,645 -2.00 0.00 - - -10,042
Sale and/or Maturity of Investments		 285 704 169 260 60 50 7.00 456 601 575 46
Other Investing Activities, net		 -33 -19 1,124 -14 -289 -467 -57 -20 5.00 129 -172
Net Cash From Financing Activities		 3,758 -4,269 -2,245 -2,814 1,216 -2,425 -3,009 -5,755 -3,556 2,638 4,751
Net Cash From Continuing Financing Activities		 3,758 -4,269 -2,245 -2,814 1,216 -2,425 -3,009 -5,755 -3,556 2,638 4,751
Repayment of Debt		 -47 -1,948 -6.00 -829 -220 -32 -581 -2,560 -146 16 56
Repurchase of Common Equity		 -338 -466 -393 -122 -251 -444 -489 -1,164 -1,345 -1,323 -1,252
Payment of Dividends		 -1,885 -1,855 -1,852 -1,950 -1,986 -1,953 -1,951 -2,050 -2,077 -2,031 -2,018
Issuance of Debt		 - -7.00 - - - -1.00 - - - 5,962 7,918
Other Financing Activities, net		 82 7.00 6.00 87 73 5.00 12 19 12 14 47
Effect of Exchange Rate Changes		 -93 - - -138 - - - 156 374 10 23

Annual Balance Sheets for Merck & Co., Inc.

This table presents Merck & Co., Inc.'s assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 101,677 95,377 87,872 82,637 84,397 91,588 105,694 109,160 106,675 117,106 136,866
Total Current Assets		 29,751 30,614 24,766 25,875 27,483 27,764 30,266 35,722 32,168 38,782 43,516
Cash & Equivalents		 8,524 6,515 6,092 7,965 9,676 8,050 8,096 12,694 6,841 13,242 14,565
Short-Term Investments		 4,903 7,826 2,406 899 774 - 0.00 498 252 447 0.00
Accounts Receivable		 6,484 7,018 6,873 7,071 6,778 6,803 9,230 9,450 10,349 10,278 11,775
Inventories, net		 4,700 4,866 5,096 5,440 5,978 5,554 5,953 5,911 6,358 6,109 6,658
Other Current Assets		 5,140 4,389 4,299 4,500 4,277 4,674 6,987 7,169 8,368 8,706 10,518
Plant, Property, & Equipment, net		 12,507 12,026 12,439 13,291 15,053 17,000 19,279 21,422 23,051 23,779 25,316
Plant, Property & Equipment, gross		 28,430 27,775 29,041 29,615 32,739 35,162 37,471 39,407 41,317 42,934 47,230
Accumulated Depreciation		 15,923 15,749 16,602 16,324 17,686 18,162 18,192 17,985 18,266 19,155 21,914
Total Noncurrent Assets		 59,419 52,737 50,667 43,471 41,861 46,824 56,149 52,016 51,456 54,545 68,034
Long-Term Investments		 13,039 11,416 12,125 6,233 1,469 785 370 1,015 252 463 956
Goodwill		 17,723 18,162 18,284 18,253 19,425 18,882 21,264 21,204 21,197 21,668 21,579
Intangible Assets		 22,602 17,305 14,183 13,104 14,196 14,101 22,933 20,269 18,011 16,370 26,681
Other Noncurrent Operating Assets		 - - - - 6,771 - - 9,528 11,996 16,044 18,818
Total Liabilities & Shareholders' Equity		 101,677 95,377 87,872 82,637 84,397 91,588 105,694 109,160 106,675 117,106 136,866
Total Liabilities		 56,910 55,069 53,303 55,755 58,396 66,184 67,437 63,102 69,040 70,734 84,204
Total Current Liabilities		 19,201 17,204 18,614 22,206 22,220 27,327 23,872 24,239 25,694 28,420 28,327
Short-Term Debt		 2,583 568 3,057 5,308 3,610 6,431 2,412 1,946 1,372 2,649 2,589
Accounts Payable		 2,533 2,807 3,102 3,318 3,738 4,327 4,609 4,264 3,922 4,079 4,404
Dividends Payable		 1,309 1,316 1,320 1,458 1,587 1,674 1,768 1,884 1,985 2,084 2,140
Current Deferred & Payable Income Tax Liabilities		 1,560 2,239 708 1,971 736 1,597 1,224 1,986 2,649 3,914 4,726
Other Current Liabilities		 11,216 10,274 10,427 10,151 12,549 12,212 13,859 14,159 15,766 15,694 14,468
Total Noncurrent Liabilities		 37,709 37,865 34,689 33,549 36,176 38,857 43,565 38,863 43,346 42,314 55,877
Long-Term Debt		 23,829 24,274 21,353 19,806 22,736 25,360 30,690 28,745 33,683 34,462 46,750
Noncurrent Deferred & Payable Income Tax Liabilities		 6,535 5,077 2,219 1,702 1,470 1,005 3,441 1,795 871 1,387 1,439
Other Noncurrent Operating Liabilities		 7,345 8,514 11,117 12,041 11,970 12,306 9,434 8,323 8,792 6,465 7,688
Total Equity & Noncontrolling Interests		 44,767 40,308 34,569 26,882 26,001 25,404 38,257 46,058 37,635 46,372 52,662
Total Preferred & Common Equity		 44,676 40,088 34,336 26,701 25,907 25,317 38,184 45,991 37,581 46,313 52,606
Total Common Equity		 44,676 40,088 34,336 26,701 25,907 25,317 38,184 45,991 37,581 46,313 52,606
Common Stock		 42,010 41,727 41,690 40,596 41,448 41,376 46,026 46,167 46,297 46,492 46,817
Retained Earnings		 45,348 44,133 41,350 42,579 46,602 47,362 53,696 61,081 53,895 63,069 73,075
Treasury Stock		 -38,534 -40,546 -43,794 -50,929 -55,950 -56,787 -57,109 -56,489 -57,450 -58,303 -62,999
Accumulated Other Comprehensive Income / (Loss)		 -4,148 -5,226 -4,910 -5,545 -6,193 -6,634 -4,429 -4,768 -5,161 -4,945 -4,287
Noncontrolling Interest		 91 220 233 181 94 87 73 67 54 59 56

Quarterly Balance Sheets for Merck & Co., Inc.

This table presents Merck & Co., Inc.'s assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 107,796 104,469 106,727 106,675 105,849 112,630 117,532 117,106 115,122 117,523 129,546
Total Current Assets		 33,402 29,977 31,954 32,168 31,445 38,205 40,361 38,782 35,503 37,065 47,557
Cash & Equivalents		 9,707 5,660 8,605 6,841 5,579 11,304 14,593 13,242 8,629 8,007 18,169
Short-Term Investments		 680 718 168 252 40 50 0.00 447 599 615 45
Accounts Receivable		 10,415 11,030 10,394 10,349 11,366 11,642 11,381 10,278 10,790 11,846 12,120
Inventories, net		 5,863 5,930 6,131 6,358 6,510 6,469 6,244 6,109 6,196 6,601 6,444
Other Current Assets		 - - 6,656 8,368 7,950 8,740 8,143 8,706 9,289 9,996 10,779
Plant, Property, & Equipment, net		 21,758 22,231 22,526 23,051 23,045 23,221 23,446 23,779 24,793 25,236 25,639
Total Noncurrent Assets		 52,636 52,261 52,247 51,456 51,359 51,204 53,725 54,545 54,826 55,222 56,350
Long-Term Investments		 1,290 1,214 1,306 252 280 357 575 463 616 774 1,117
Goodwill		 21,209 21,195 21,183 21,197 21,181 21,161 21,697 21,668 21,684 21,591 21,587
Intangible Assets		 19,857 19,665 19,199 18,011 17,572 16,984 17,010 16,370 15,758 15,193 15,313
Other Noncurrent Operating Assets		 - - 10,559 11,996 12,326 12,702 14,443 16,044 16,768 17,664 18,333
Total Liabilities & Shareholders' Equity		 107,796 104,469 106,727 106,675 105,849 112,630 117,532 117,106 115,122 117,523 129,546
Total Liabilities		 60,891 65,727 65,427 69,040 65,425 68,982 72,972 70,734 66,722 68,463 77,639
Total Current Liabilities		 23,131 23,394 23,094 25,694 25,099 26,060 29,586 28,420 25,174 26,037 28,628
Short-Term Debt		 2,672 2,839 887 1,372 3,077 3,071 3,149 2,649 1,360 1,434 1,405
Accounts Payable		 3,680 3,442 3,509 3,922 3,514 3,519 3,586 4,079 3,784 3,892 4,147
Dividends Payable		 1,907 1,877 1,877 1,985 2,008 1,981 1,982 2,084 2,077 2,053 2,042
Current Deferred & Payable Income Tax Liabilities		 1,872 1,489 1,981 2,649 2,398 2,777 4,330 3,914 5,181 4,156 4,848
Other Current Liabilities		 13,000 13,747 14,840 15,766 14,102 14,712 16,539 15,694 12,772 14,502 16,186
Total Noncurrent Liabilities		 37,760 42,333 42,333 43,346 40,326 42,922 43,386 42,314 41,548 42,426 49,011
Long-Term Debt		 28,074 34,072 33,972 33,683 31,142 34,717 34,982 34,462 33,484 33,968 39,969
Noncurrent Deferred & Payable Income Tax Liabilities		 1,442 996 1,018 871 922 876 864 1,387 1,409 1,427 1,381
Other Noncurrent Operating Liabilities		 8,244 7,265 7,343 8,792 8,262 7,329 7,540 6,465 6,655 7,031 7,661
Total Equity & Noncontrolling Interests		 46,905 38,742 41,300 37,635 40,424 43,648 44,560 46,372 48,400 49,060 51,907
Total Preferred & Common Equity		 46,834 38,693 41,246 37,581 40,364 43,582 44,502 46,313 48,335 48,993 51,850
Total Common Equity		 46,834 38,693 41,246 37,581 40,364 43,582 44,502 46,313 48,335 48,993 51,850
Common Stock		 46,255 46,007 46,146 46,297 46,386 46,150 46,318 46,492 46,604 46,432 46,620
Retained Earnings		 62,039 54,198 57,082 53,895 56,697 60,187 61,384 63,069 66,097 68,477 72,231
Treasury Stock		 -56,577 -56,612 -57,066 -57,450 -57,445 -57,394 -57,829 -58,303 -59,401 -60,495 -61,799
Accumulated Other Comprehensive Income / (Loss)		 -4,883 -4,900 -4,916 -5,161 -5,274 -5,361 -5,371 -4,945 -4,965 -5,421 -5,202
Noncontrolling Interest		 71 49 54 54 60 66 58 59 65 67 57

Annual Metrics And Ratios for Merck & Co., Inc.

This table displays calculated financial ratios and metrics derived from Merck & Co., Inc.'s official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -6.48% 0.78% 0.79% 5.41% -7.50% 6.13% 17.31% 21.72% 1.40% 6.74% 1.31%
EBITDA Growth		 -50.88% -13.98% 10.53% 18.07% -20.72% -10.80% 82.83% 19.07% -71.69% 324.15% 10.11%
EBIT Growth		 -68.75% -13.74% 39.97% 33.43% -17.58% -18.24% 136.72% 18.48% -88.51% 955.37% 5.67%
NOPAT Growth		 46.09% -28.30% -45.56% 164.57% -3.39% -32.78% 191.00% 41.99% -97.04% 3,540.91% 7.49%
Net Income Growth		 -62.64% -11.62% -38.65% 156.12% 57.58% -27.54% 84.54% 11.32% -97.40% 4,444.56% 6.60%
EPS Growth		 -61.67% -9.62% -38.30% 166.67% 64.22% -27.03% 84.89% 11.09% -97.55% 4,714.29% 8.01%
Operating Cash Flow Growth		 56.94% -17.24% -37.83% 69.31% -18.66% -14.26% 72.27% 45.52% -31.89% 65.06% -23.27%
Free Cash Flow Firm Growth		 -84.99% 378.91% -65.31% 121.27% -71.65% -80.31% -2,095.24% 299.86% -115.13% 635.23% -90.87%
Invested Capital Growth		 8.88% -11.54% -2.54% -3.32% 9.54% 8.17% 42.27% -0.36% 4.51% 6.07% 24.09%
Revenue Q/Q Growth		 -0.67% -0.25% 0.80% 1.35% -14.90% 13.79% 9.79% 0.52% 1.35% 1.57% 1.21%
EBITDA Q/Q Growth		 -48.31% -20.09% 40.31% 4.40% -11.84% 18.46% 74.24% -1.64% -48.78% 35.86% 1.97%
EBIT Q/Q Growth		 -67.06% -31.80% 98.45% 9.10% -36.42% -24.67% 111.96% -2.35% -74.64% 45.31% -3.44%
NOPAT Q/Q Growth		 35.91% -35.00% -15.78% 90.70% -40.40% -29.08% 168.05% -3.72% -90.24% 41.46% -2.74%
Net Income Q/Q Growth		 -58.73% -28.46% -15.75% 83.39% 6.18% -38.59% 81.39% -4.85% -91.84% 40.86% -4.10%
EPS Q/Q Growth		 -58.06% -28.06% -17.14% 85.60% 6.42% -38.50% 80.99% -4.99% -92.22% 41.30% -3.96%
Operating Cash Flow Q/Q Growth		 72.77% -5.59% 6.38% -3.76% -27.41% 71.36% 14.73% -3.37% -24.34% 17.54% -3.47%
Free Cash Flow Firm Q/Q Growth		 2,093.34% 3.38% -33.68% 5.77% -58.35% 135.93% -635.94% 192.71% -281.89% 23.49% -90.43%
Invested Capital Q/Q Growth		 -5.04% -10.86% -8.57% -3.29% -5.20% -10.62% 20.83% -0.09% -0.92% 2.75% 16.62%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 62.19% 64.75% 67.82% 68.06% 69.29% 67.20% 72.02% 70.63% 73.17% 76.32% 74.80%
EBITDA Margin		 29.81% 25.45% 27.91% 31.26% 26.79% 22.52% 35.10% 34.33% 9.58% 38.08% 41.39%
Operating Margin		 17.54% 12.18% 15.01% 19.62% 18.66% 11.98% 25.74% 30.27% 3.92% 31.03% 32.64%
EBIT Margin		 13.67% 11.70% 16.25% 20.57% 18.33% 14.12% 28.50% 27.74% 3.14% 31.07% 32.41%
Profit (Net Income) Margin		 11.29% 9.90% 6.03% 14.64% 24.95% 17.03% 26.79% 24.50% 0.63% 26.70% 28.09%
Tax Burden Percent		 82.56% 84.59% 37.08% 71.18% 136.09% 120.60% 94.02% 88.34% 19.96% 85.94% 86.69%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 17.44% 15.41% 62.92% 28.82% 21.82% 22.86% 10.96% 11.66% 80.04% 14.06% 13.31%
Return on Invested Capital (ROIC)		 12.96% 9.46% 5.55% 15.14% 14.20% 8.77% 20.28% 24.56% 0.71% 24.67% 22.99%
ROIC Less NNEP Spread (ROIC-NNEP)		 60.82% -9.85% 12.29% 18.59% 43.68% 26.71% 28.39% 18.64% 0.33% 24.74% 22.56%
Return on Net Nonoperating Assets (RNNOA)		 -3.42% -0.19% 0.90% 5.02% 22.71% 18.74% 20.72% 9.90% 0.19% 16.12% 13.89%
Return on Equity (ROE)		 9.53% 9.26% 6.46% 20.16% 36.91% 27.51% 41.00% 34.46% 0.90% 40.79% 36.88%
Cash Return on Invested Capital (CROIC)		 4.45% 21.71% 8.12% 18.52% 5.10% 0.92% -14.62% 24.92% -3.69% 18.78% 1.49%
Operating Return on Assets (OROA)		 5.41% 4.73% 7.12% 10.21% 8.59% 6.66% 14.07% 15.31% 1.75% 17.82% 16.59%
Return on Assets (ROA)		 4.46% 4.00% 2.64% 7.26% 11.69% 8.04% 13.23% 13.52% 0.35% 15.31% 14.38%
Return on Common Equity (ROCE)		 9.51% 9.23% 6.42% 20.02% 36.72% 27.41% 40.89% 34.40% 0.90% 40.73% 36.84%
Return on Equity Simple (ROE_SIMPLE)		 9.98% 9.83% 7.04% 23.19% 37.67% 27.93% 34.17% 31.58% 1.00% 36.99% 0.00%
Net Operating Profit after Tax (NOPAT)		 5,720 4,101 2,233 5,907 5,707 3,836 11,164 15,852 470 17,112 18,394
NOPAT Margin		 14.48% 10.30% 5.56% 13.97% 14.59% 9.24% 22.92% 26.74% 0.78% 26.67% 28.29%
Net Nonoperating Expense Percent (NNEP)		 -47.86% 19.31% -6.73% -3.45% -29.48% -17.94% -8.12% 5.92% 0.39% -0.08% 0.43%
Return On Investment Capital (ROIC_SIMPLE)		 8.04% 6.29% 3.79% 11.36% 10.90% 6.71% 15.64% 20.65% 0.65% 20.50% 18.03%
Cost of Revenue to Revenue		 37.81% 35.25% 32.18% 31.94% 30.72% 32.80% 27.98% 29.37% 26.83% 23.68% 25.20%
SG&A Expenses to Revenue		 26.11% 25.16% 25.11% 23.89% 24.17% 21.57% 19.78% 16.94% 17.47% 16.86% 16.51%
R&D to Revenue		 16.97% 25.78% 25.77% 23.06% 24.86% 32.27% 25.14% 22.85% 50.79% 27.95% 24.29%
Operating Expenses to Revenue		 44.65% 52.58% 52.81% 48.44% 50.63% 55.22% 46.28% 40.36% 69.26% 45.29% 42.16%
Earnings before Interest and Taxes (EBIT)		 5,401 4,659 6,521 8,701 7,171 5,863 13,879 16,444 1,889 19,936 21,067
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 11,776 10,130 11,197 13,220 10,481 9,349 17,093 20,353 5,761 24,435 26,905
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.38 3.01 3.43 5.89 7.26 6.85 4.61 5.74 7.09 5.39 4.97
Price to Tangible Book Value (P/TBV)		 24.46 26.15 62.94 0.00 0.00 0.00 0.00 58.45 0.00 30.15 60.11
Price to Revenue (P/Rev)		 2.69 3.04 2.93 3.72 4.81 4.18 3.62 4.45 4.44 3.89 4.02
Price to Earnings (P/E)		 23.96 30.83 49.14 25.26 19.11 24.55 13.51 18.19 730.45 14.58 14.31
Dividend Yield		 4.75% 4.22% 4.38% 3.29% 3.06% 3.62% 3.79% 2.69% 2.81% 3.16% 3.12%
Earnings Yield		 4.17% 3.24% 2.04% 3.96% 5.23% 4.07% 7.40% 5.50% 0.14% 6.86% 6.99%
Enterprise Value to Invested Capital (EV/IC)		 2.31 2.95 3.07 4.36 4.82 4.32 3.11 4.36 4.37 3.82 3.33
Enterprise Value to Revenue (EV/Rev)		 2.70 3.02 3.03 3.96 5.18 4.73 4.12 4.73 4.90 4.25 4.54
Enterprise Value to EBITDA (EV/EBITDA)		 9.04 11.86 10.87 12.66 19.33 21.02 11.75 13.79 51.10 11.15 10.97
Enterprise Value to EBIT (EV/EBIT)		 19.71 25.79 18.66 19.23 28.26 33.52 14.47 17.07 155.84 13.67 14.01
Enterprise Value to NOPAT (EV/NOPAT)		 18.61 29.30 54.49 28.33 35.51 51.22 17.99 17.70 626.34 15.92 16.05
Enterprise Value to Operating Cash Flow (EV/OCF)		 8.49 11.58 18.86 15.32 22.81 25.80 15.30 14.70 22.63 12.69 17.92
Enterprise Value to Free Cash Flow (EV/FCFF)		 54.16 12.76 37.25 23.16 98.90 487.13 0.00 17.45 0.00 20.92 248.24
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.59 0.62 0.71 0.93 1.01 1.25 0.87 0.67 0.93 0.80 0.94
Long-Term Debt to Equity		 0.53 0.60 0.62 0.74 0.87 1.00 0.80 0.62 0.90 0.74 0.89
Financial Leverage		 -0.06 0.02 0.07 0.27 0.52 0.70 0.73 0.53 0.57 0.65 0.62
Leverage Ratio		 2.14 2.32 2.45 2.77 3.16 3.42 3.10 2.55 2.58 2.66 2.56
Compound Leverage Factor		 2.14 2.32 2.45 2.77 3.16 3.42 3.10 2.55 2.58 2.66 2.56
Debt to Total Capital		 37.11% 38.13% 41.39% 48.30% 50.33% 55.58% 46.39% 39.99% 48.23% 44.45% 48.37%
Short-Term Debt to Total Capital		 3.63% 0.87% 5.18% 10.21% 6.90% 11.24% 3.38% 2.54% 1.89% 3.17% 2.54%
Long-Term Debt to Total Capital		 33.48% 37.26% 36.20% 38.09% 43.43% 44.34% 43.01% 37.45% 46.34% 41.28% 45.83%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.13% 0.34% 0.40% 0.35% 0.18% 0.15% 0.10% 0.09% 0.07% 0.07% 0.05%
Common Equity to Total Capital		 62.77% 61.53% 58.22% 51.35% 49.49% 44.26% 53.51% 59.92% 51.70% 55.48% 51.57%
Debt to EBITDA		 2.24 2.45 2.18 1.90 2.51 3.40 1.94 1.51 6.08 1.52 1.83
Net Debt to EBITDA		 0.00 -0.09 0.34 0.76 1.38 2.46 1.44 0.81 4.81 0.94 1.26
Long-Term Debt to EBITDA		 2.02 2.40 1.91 1.50 2.17 2.71 1.80 1.41 5.85 1.41 1.74
Debt to NOPAT		 4.62 6.06 10.93 4.25 4.62 8.29 2.97 1.94 74.58 2.17 2.68
Net Debt to NOPAT		 -0.01 -0.22 1.70 1.70 2.53 5.98 2.21 1.04 58.96 1.34 1.84
Long-Term Debt to NOPAT		 4.17 5.92 9.56 3.35 3.98 6.61 2.75 1.81 71.67 2.01 2.54
Altman Z-Score		 2.43 2.71 2.77 3.33 3.52 2.97 3.24 4.46 3.72 4.09 3.73
Noncontrolling Interest Sharing Ratio		 0.25% 0.37% 0.61% 0.67% 0.52% 0.35% 0.25% 0.17% 0.14% 0.13% 0.12%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.55 1.78 1.33 1.17 1.24 1.02 1.27 1.47 1.25 1.36 1.54
Quick Ratio		 1.04 1.24 0.83 0.72 0.78 0.54 0.73 0.93 0.68 0.84 0.93
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 1,966 9,414 3,266 7,226 2,049 403 -8,049 16,087 -2,434 13,027 1,189
Operating Cash Flow to CapEx		 977.24% 642.87% 341.68% 417.67% 263.70% 171.98% 295.01% 435.16% 336.68% 636.65% 400.58%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.40 0.40 0.44 0.50 0.47 0.47 0.49 0.55 0.56 0.57 0.51
Accounts Receivable Turnover		 6.03 5.90 5.78 6.07 5.65 6.11 6.08 6.35 6.07 6.22 5.90
Inventory Turnover		 2.91 2.93 2.59 2.56 2.10 2.36 2.37 2.94 2.63 2.44 2.57
Fixed Asset Turnover		 3.08 3.25 3.28 3.29 2.76 2.59 2.69 2.91 2.70 2.74 2.65
Accounts Payable Turnover		 5.79 5.25 4.37 4.21 3.41 3.38 3.05 3.92 3.94 3.80 3.86
Days Sales Outstanding (DSO)		 60.57 61.90 63.19 60.17 64.61 59.70 60.08 57.51 60.11 58.67 61.91
Days Inventory Outstanding (DIO)		 125.52 124.43 140.80 142.34 173.42 154.54 154.12 124.36 138.85 149.76 142.23
Days Payable Outstanding (DPO)		 63.03 69.46 83.52 86.73 107.17 108.08 119.68 93.01 92.64 96.11 94.50
Cash Conversion Cycle (CCC)		 123.06 116.87 120.47 115.77 130.86 106.16 94.51 88.86 106.31 112.31 109.63
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 46,022 40,709 39,676 38,357 42,015 45,448 64,661 64,426 67,330 71,415 88,620
Invested Capital Turnover		 0.89 0.92 1.00 1.08 0.97 0.95 0.88 0.92 0.91 0.93 0.81
Increase / (Decrease) in Invested Capital		 3,754 -5,313 -1,033 -1,319 3,658 3,433 19,213 -235 2,904 4,085 17,205
Enterprise Value (EV)		 106,457 120,150 121,657 167,339 202,640 196,515 200,794 280,644 294,380 272,511 295,132
Market Capitalization		 106,420 120,845 117,637 157,141 188,119 173,472 176,085 264,093 266,616 249,493 261,258
Book Value per Share		 $15.99 $14.54 $12.60 $10.27 $10.18 $10.01 $15.12 $18.14 $14.83 $18.31 $21.19
Tangible Book Value per Share		 $1.56 $1.68 $0.69 ($1.79) ($3.03) ($3.03) ($2.38) $1.78 ($0.64) $3.27 $1.75
Total Capital		 71,179 65,150 58,979 51,996 52,347 57,195 71,359 76,749 72,690 83,483 102,001
Total Debt		 26,412 24,842 24,410 25,114 26,346 31,791 33,102 30,691 35,055 37,111 49,339
Total Long-Term Debt		 23,829 24,274 21,353 19,806 22,736 25,360 30,690 28,745 33,683 34,462 46,750
Net Debt		 -54 -915 3,787 10,017 14,427 22,956 24,636 16,484 27,710 22,959 33,818
Capital Expenditures (CapEx)		 1,283 1,614 1,888 2,615 3,369 4,429 4,448 4,388 3,863 3,372 4,112
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -294 -363 711 113 -1,577 -1,182 710 237 753 -678 3,213
Debt-free Net Working Capital (DFNWC)		 13,133 13,978 9,209 8,977 8,873 6,868 8,806 13,429 7,846 13,011 17,778
Net Working Capital (NWC)		 10,550 13,410 6,152 3,669 5,263 437 6,394 11,483 6,474 10,362 15,189
Net Nonoperating Expense (NNE)		 1,261 160 -185 -286 -4,052 -3,235 -1,885 1,326 93 -21 131
Net Nonoperating Obligations (NNO)		 1,255 401 5,107 11,475 16,014 20,044 26,404 18,368 29,695 25,043 35,958
Total Depreciation and Amortization (D&A)		 6,375 5,471 4,676 4,519 3,310 3,486 3,214 3,909 3,872 4,499 5,838
Debt-free, Cash-free Net Working Capital to Revenue		 -0.74% -0.91% 1.77% 0.27% -4.03% -2.85% 1.46% 0.40% 1.25% -1.06% 4.94%
Debt-free Net Working Capital to Revenue		 33.25% 35.11% 22.95% 21.23% 22.68% 16.54% 18.08% 22.65% 13.05% 20.28% 27.35%
Net Working Capital to Revenue		 26.71% 33.69% 15.33% 8.68% 13.45% 1.05% 13.13% 19.37% 10.77% 16.15% 23.36%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.58 $1.42 $0.88 $2.34 $3.84 $2.79 $5.16 $5.73 $0.14 $6.76 $7.30
Adjusted Weighted Average Basic Shares Outstanding		 2.78B 2.75B 2.70B 2.58B 2.54B 2.53B 2.53B 2.54B 2.53B 2.53B 2.47B
Adjusted Diluted Earnings per Share		 $1.56 $1.41 $0.87 $2.32 $3.81 $2.78 $5.14 $5.71 $0.14 $6.74 $7.28
Adjusted Weighted Average Diluted Shares Outstanding		 2.78B 2.75B 2.70B 2.58B 2.54B 2.53B 2.53B 2.54B 2.53B 2.53B 2.47B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.78B 2.75B 2.70B 2.58B 2.54B 2.53B 2.53B 2.54B 2.53B 2.53B 2.47B
Normalized Net Operating Profit after Tax (NOPAT)		 6,231 4,652 4,758 6,357 6,196 4,280 11,753 16,150 2,068 17,378 19,165
Normalized NOPAT Margin		 15.77% 11.69% 11.86% 15.03% 15.84% 10.31% 24.13% 27.24% 3.44% 27.08% 29.48%
Pre Tax Income Margin		 13.67% 11.70% 16.25% 20.57% 18.33% 14.12% 28.50% 27.74% 3.14% 31.07% 32.41%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 114.76% 130.02% 213.69% 83.51% 58.36% 87.89% 50.66% 48.27% 1,974.80% 45.76% 44.77%
Augmented Payout Ratio		 208.63% 217.15% 379.69% 230.31% 107.34% 106.01% 57.09% 48.27% 2,331.83% 53.38% 72.61%

Quarterly Metrics And Ratios for Merck & Co., Inc.

This table displays calculated financial ratios and metrics derived from Merck & Co., Inc.'s official financial filings.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 3.03% 6.71% 5.79% 8.89% 7.16% 4.35% 6.79% -1.56% -1.90% 3.72% 4.97%
EBITDA Growth		 -181.70% 46.06% -124.56% 43.37% 261.06% -20.47% 596.03% 5.23% -14.29% 49.72% 9.67%
EBIT Growth		 -218.90% 56.85% -158.24% 55.34% 212.58% -27.22% 303.81% 4.11% -16.77% 64.91% -17.99%
NOPAT Growth		 -183.38% 33.33% -146.62% 63.77% 252.16% -37.49% 380.33% 6.66% -19.59% 83.90% -13.56%
Net Income Growth		 -251.23% 46.02% -140.64% 68.74% 191.44% -33.45% 405.38% 6.67% -18.92% 83.08% -20.86%
EPS Growth		 -251.61% 45.31% -140.68% 68.47% 191.06% -33.33% 410.42% 7.49% -17.76% 87.10% -20.13%
Operating Cash Flow Growth		 -13.90% 37.75% -94.45% 130.77% 52.19% 20.40% 1,302.44% -19.09% -41.58% -15.81% -17.19%
Free Cash Flow Firm Growth		 24.24% 118.85% -234.26% 551.22% 152.05% 7.77% 94.74% -82.34% -126.57% -160.77% -6,058.94%
Invested Capital Growth		 5.36% 5.39% 4.51% 4.23% 2.53% 2.28% 6.07% 6.68% 7.55% 9.33% 24.09%
Revenue Q/Q Growth		 3.78% 6.17% -8.34% 7.82% 2.14% 3.38% -6.20% -0.61% 1.78% 9.30% -5.07%
EBITDA Q/Q Growth		 -195.50% 249.68% -116.31% 714.97% 7.27% -26.09% 1.72% 30.46% -12.63% 29.11% -25.48%
EBIT Q/Q Growth		 -246.16% 205.34% -136.41% 377.13% 5.93% -31.90% 1.96% 41.56% -15.31% 34.93% -49.30%
NOPAT Q/Q Growth		 -224.89% 234.38% -128.35% 444.20% 16.03% -44.80% 27.14% 30.96% -12.52% 26.26% -40.24%
Net Income Q/Q Growth		 -311.40% 179.54% -125.81% 488.83% 14.56% -42.12% 18.44% 35.82% -12.92% 30.69% -48.80%
EPS Q/Q Growth		 -311.71% 179.15% -125.81% 489.58% 14.44% -42.06% 20.16% 34.90% -12.44% 31.82% -48.71%
Operating Cash Flow Q/Q Growth		 176.62% 108.34% -96.81% 1,156.10% 82.43% 64.82% -62.87% -27.54% 31.72% 137.53% -63.47%
Free Cash Flow Firm Q/Q Growth		 -2,598.96% 119.26% -410.10% 143.64% 99.72% -60.13% -115.14% 246.48% -400.50% 8.78% -1,433.80%
Invested Capital Q/Q Growth		 3.03% -2.83% -0.92% 5.08% 1.35% -3.07% 2.75% 5.69% 2.18% -1.46% 16.62%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 73.24% 73.29% 73.26% 77.56% 76.76% 75.51% 75.50% 77.98% 77.50% 77.69% 66.15%
EBITDA Margin		 -29.48% 41.56% -7.40% 42.18% 44.30% 31.67% 34.35% 45.09% 38.71% 45.72% 35.89%
Operating Margin		 -34.34% 36.00% -13.44% 35.73% 37.54% 23.58% 27.52% 37.79% 31.58% 37.67% 23.48%
EBIT Margin		 -35.48% 35.21% -13.98% 35.94% 37.28% 24.55% 26.69% 38.01% 31.63% 39.04% 20.85%
Profit (Net Income) Margin		 -39.72% 29.76% -8.38% 30.22% 33.89% 18.98% 23.96% 32.75% 28.01% 33.50% 18.07%
Tax Burden Percent		 111.94% 84.52% 59.92% 84.07% 90.93% 77.29% 89.78% 86.14% 88.58% 85.80% 86.64%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 15.48% 0.00% 15.93% 9.07% 22.71% 10.22% 13.86% 11.42% 14.20% 13.36%
Return on Invested Capital (ROIC)		 -20.56% 27.25% -8.59% 26.61% 30.11% 16.75% 22.85% 28.46% 23.92% 28.53% 16.53%
ROIC Less NNEP Spread (ROIC-NNEP)		 -29.26% 26.80% -7.96% 26.72% 29.98% 17.24% 22.43% 28.56% 23.94% 29.37% 15.30%
Return on Net Nonoperating Assets (RNNOA)		 -19.34% 14.55% -4.57% 15.70% 21.56% 10.36% 14.61% 18.46% 14.49% 14.93% 9.43%
Return on Equity (ROE)		 -39.91% 41.81% -13.16% 42.31% 51.67% 27.11% 37.46% 46.92% 38.41% 43.46% 25.96%
Cash Return on Invested Capital (CROIC)		 -0.11% 2.02% -3.69% -0.50% 17.19% 15.35% 18.78% 17.37% 14.70% 17.08% 1.49%
Operating Return on Assets (OROA)		 -19.56% 19.53% -7.79% 20.66% 21.46% 13.83% 15.31% 21.99% 17.48% 20.30% 10.68%
Return on Assets (ROA)		 -21.90% 16.51% -4.67% 17.37% 19.51% 10.69% 13.74% 18.94% 15.49% 17.42% 9.25%
Return on Common Equity (ROCE)		 -39.85% 41.75% -13.14% 42.25% 51.60% 27.08% 37.41% 46.85% 38.35% 43.41% 25.93%
Return on Equity Simple (ROE_SIMPLE)		 8.07% 11.20% 0.00% 5.75% 31.55% 27.33% 0.00% 36.10% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3,614 4,856 -1,377 4,739 5,499 3,036 3,860 5,055 4,422 5,583 3,336
NOPAT Margin		 -24.04% 30.43% -9.41% 30.04% 34.13% 18.23% 24.70% 32.55% 27.98% 32.32% 20.34%
Net Nonoperating Expense Percent (NNEP)		 8.69% 0.46% -0.63% -0.11% 0.13% -0.49% 0.42% -0.11% -0.02% -0.83% 1.22%
Return On Investment Capital (ROIC_SIMPLE)		 -4.78% 6.38% -1.89% 6.35% 6.75% 3.67% 4.62% 6.07% 5.24% 5.98% 3.27%
Cost of Revenue to Revenue		 26.76% 26.71% 26.74% 22.44% 23.24% 24.49% 24.50% 22.02% 22.50% 22.31% 33.85%
SG&A Expenses to Revenue		 17.97% 15.78% 19.16% 15.74% 17.00% 16.40% 18.32% 16.43% 16.76% 15.24% 17.68%
R&D to Revenue		 88.60% 20.72% 65.80% 25.31% 21.72% 35.19% 29.34% 23.32% 25.61% 24.51% 23.70%
Operating Expenses to Revenue		 107.58% 37.29% 86.71% 41.83% 39.22% 51.92% 47.98% 40.20% 45.91% 40.02% 42.67%
Earnings before Interest and Taxes (EBIT)		 -5,335 5,620 -2,046 5,670 6,006 4,090 4,170 5,903 4,999 6,745 3,420
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4,432 6,634 -1,082 6,654 7,138 5,276 5,367 7,002 6,118 7,899 5,886
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 7.20 6.07 7.09 8.05 7.03 6.36 5.39 4.69 4.06 4.04 4.97
Price to Tangible Book Value (P/TBV)		 0.00 289.71 0.00 201.58 56.35 48.86 30.15 20.81 16.28 14.02 60.11
Price to Revenue (P/Rev)		 4.78 4.22 4.44 5.29 4.90 4.48 3.89 3.55 3.12 3.26 4.02
Price to Earnings (P/E)		 89.57 54.32 730.45 140.82 22.30 23.31 14.58 13.01 12.12 11.01 14.31
Dividend Yield		 2.62% 2.96% 2.81% 2.34% 2.51% 2.76% 3.16% 3.52% 4.04% 3.86% 3.12%
Earnings Yield		 1.12% 1.84% 0.14% 0.71% 4.48% 4.29% 6.86% 7.69% 8.25% 9.08% 6.99%
Enterprise Value to Invested Capital (EV/IC)		 4.40 4.05 4.37 4.99 4.64 4.40 3.82 3.34 2.92 3.05 3.33
Enterprise Value to Revenue (EV/Rev)		 5.28 4.64 4.90 5.75 5.32 4.85 4.25 3.94 3.53 3.61 4.54
Enterprise Value to EBITDA (EV/EBITDA)		 33.64 24.46 51.10 45.42 17.19 17.02 11.15 10.16 9.46 8.78 10.97
Enterprise Value to EBIT (EV/EBIT)		 56.92 36.94 155.84 90.34 21.80 22.31 13.67 12.48 11.73 10.62 14.01
Enterprise Value to NOPAT (EV/NOPAT)		 88.55 57.15 626.34 139.96 23.84 25.31 15.92 14.45 13.75 12.25 16.05
Enterprise Value to Operating Cash Flow (EV/OCF)		 20.43 16.01 22.63 23.93 19.92 16.76 12.69 12.06 12.13 13.58 17.92
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 205.61 0.00 0.00 27.31 29.02 20.92 19.82 20.55 18.65 248.24
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.95 0.84 0.93 0.85 0.87 0.86 0.80 0.72 0.72 0.80 0.94
Long-Term Debt to Equity		 0.88 0.82 0.90 0.77 0.80 0.79 0.74 0.69 0.69 0.77 0.89
Financial Leverage		 0.66 0.54 0.57 0.59 0.72 0.60 0.65 0.65 0.61 0.51 0.62
Leverage Ratio		 2.58 2.49 2.58 2.45 2.64 2.61 2.66 2.49 2.48 2.56 2.56
Compound Leverage Factor		 2.58 2.49 2.58 2.45 2.64 2.61 2.66 2.49 2.48 2.56 2.56
Debt to Total Capital		 48.79% 45.77% 48.23% 45.84% 46.40% 46.11% 44.45% 41.86% 41.91% 44.35% 48.37%
Short-Term Debt to Total Capital		 3.75% 1.16% 1.89% 4.12% 3.77% 3.81% 3.17% 1.63% 1.70% 1.51% 2.54%
Long-Term Debt to Total Capital		 45.04% 44.61% 46.34% 41.72% 42.63% 42.30% 41.28% 40.22% 40.22% 42.85% 45.83%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.06% 0.07% 0.07% 0.08% 0.08% 0.07% 0.07% 0.08% 0.08% 0.06% 0.05%
Common Equity to Total Capital		 51.15% 54.16% 51.70% 54.08% 53.52% 53.82% 55.48% 58.06% 58.01% 55.58% 51.57%
Debt to EBITDA		 4.03 3.10 6.08 4.40 1.95 2.12 1.52 1.41 1.49 1.57 1.83
Net Debt to EBITDA		 3.20 2.20 4.81 3.64 1.35 1.28 0.94 1.01 1.09 0.84 1.26
Long-Term Debt to EBITDA		 3.72 3.02 5.85 4.01 1.79 1.95 1.41 1.35 1.43 1.51 1.74
Debt to NOPAT		 10.61 7.24 74.58 13.56 2.71 3.15 2.17 2.00 2.16 2.19 2.68
Net Debt to NOPAT		 8.43 5.15 58.96 11.22 1.87 1.90 1.34 1.43 1.59 1.17 1.84
Long-Term Debt to NOPAT		 9.79 7.06 71.67 12.34 2.49 2.89 2.01 1.92 2.08 2.11 2.54
Altman Z-Score		 3.74 3.87 3.60 4.56 4.27 3.82 3.64 3.67 3.35 3.24 3.30
Noncontrolling Interest Sharing Ratio		 0.15% 0.14% 0.14% 0.15% 0.14% 0.13% 0.13% 0.14% 0.14% 0.12% 0.12%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.28 1.38 1.25 1.25 1.47 1.36 1.36 1.41 1.42 1.66 1.54
Quick Ratio		 0.74 0.83 0.68 0.68 0.88 0.88 0.84 0.80 0.79 1.06 0.93
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7,169 1,380 -4,281 1,868 3,731 1,488 -225 330 -991 -904 -13,869
Operating Cash Flow to CapEx		 383.83% 855.54% 24.87% 358.89% 712.64% 1,186.59% 368.20% 188.25% 431.02% 792.50% 276.57%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.55 0.55 0.56 0.57 0.58 0.56 0.57 0.58 0.55 0.52 0.51
Accounts Receivable Turnover		 5.64 5.97 6.07 5.64 5.51 5.80 6.22 5.77 5.42 5.47 5.90
Inventory Turnover		 2.75 2.74 2.63 2.54 2.49 2.47 2.44 2.37 2.28 2.31 2.57
Fixed Asset Turnover		 2.76 2.76 2.70 2.74 2.75 2.75 2.74 2.67 2.63 2.62 2.65
Accounts Payable Turnover		 4.55 4.68 3.94 4.38 4.44 4.31 3.80 4.13 4.02 3.79 3.86
Days Sales Outstanding (DSO)		 64.70 61.16 60.11 64.74 66.22 62.90 58.67 63.26 67.38 66.77 61.91
Days Inventory Outstanding (DIO)		 132.72 133.18 138.85 143.46 146.36 147.83 149.76 153.85 160.26 157.96 142.23
Days Payable Outstanding (DPO)		 80.15 78.01 92.64 83.41 82.17 84.76 96.11 88.37 90.87 96.27 94.50
Cash Conversion Cycle (CCC)		 117.27 116.32 106.31 124.79 130.41 125.98 112.31 128.74 136.77 128.46 109.63
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 69,938 67,957 67,330 70,752 71,706 69,505 71,415 75,477 77,119 75,992 88,620
Invested Capital Turnover		 0.86 0.90 0.91 0.89 0.88 0.92 0.93 0.87 0.85 0.88 0.81
Increase / (Decrease) in Invested Capital		 3,555 3,476 2,904 2,871 1,768 1,548 4,085 4,725 5,413 6,487 17,205
Enterprise Value (EV)		 308,011 275,140 294,380 353,120 332,500 306,142 272,511 251,802 224,846 231,739 295,132
Market Capitalization		 278,643 250,306 266,616 324,740 306,357 283,121 249,493 226,737 198,773 209,639 261,258
Book Value per Share		 $15.25 $16.25 $14.83 $15.94 $17.21 $17.56 $18.31 $19.13 $19.51 $20.76 $21.19
Tangible Book Value per Share		 ($0.85) $0.34 ($0.64) $0.64 $2.15 $2.29 $3.27 $4.31 $4.86 $5.99 $1.75
Total Capital		 75,653 76,159 72,690 74,643 81,436 82,691 83,483 83,244 84,462 93,281 102,001
Total Debt		 36,911 34,859 35,055 34,219 37,788 38,131 37,111 34,844 35,402 41,374 49,339
Total Long-Term Debt		 34,072 33,972 33,683 31,142 34,717 34,982 34,462 33,484 33,968 39,969 46,750
Net Debt		 29,319 24,780 27,710 28,320 26,077 22,963 22,959 25,000 26,006 22,043 33,818
Capital Expenditures (CapEx)		 965 902 989 861 791 783 937 1,328 764 987 1,033
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 3,044 974 753 3,804 3,862 -669 -678 2,461 3,840 2,120 3,213
Debt-free Net Working Capital (DFNWC)		 9,422 9,747 7,846 9,423 15,216 13,924 13,011 11,689 12,462 20,334 17,778
Net Working Capital (NWC)		 6,583 8,860 6,474 6,346 12,145 10,775 10,362 10,329 11,028 18,929 15,189
Net Nonoperating Expense (NNE)		 2,358 106 -151 -28 38 -125 116 -30 -6.20 -204 373
Net Nonoperating Obligations (NNO)		 31,196 26,657 29,695 30,328 28,058 24,945 25,043 27,077 28,059 24,085 35,958
Total Depreciation and Amortization (D&A)		 903 1,014 964 984 1,132 1,186 1,197 1,099 1,119 1,154 2,466
Debt-free, Cash-free Net Working Capital to Revenue		 5.22% 1.64% 1.25% 6.20% 6.18% -1.06% -1.06% 3.85% 6.04% 3.30% 4.94%
Debt-free Net Working Capital to Revenue		 16.16% 16.43% 13.05% 15.35% 24.35% 22.04% 20.28% 18.29% 19.59% 31.66% 27.35%
Net Working Capital to Revenue		 11.29% 14.94% 10.77% 10.34% 19.44% 17.06% 16.15% 16.16% 17.34% 29.47% 23.36%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.35) $1.87 ($0.49) $1.88 $2.15 $1.25 $1.48 $2.01 $1.76 $2.32 $1.21
Adjusted Weighted Average Basic Shares Outstanding		 2.54B 2.53B 2.53B 2.53B 2.53B 2.53B 2.53B 2.51B 2.50B 2.48B 2.47B
Adjusted Diluted Earnings per Share		 ($2.35) $1.86 ($0.48) $1.87 $2.14 $1.24 $1.49 $2.01 $1.76 $2.32 $1.19
Adjusted Weighted Average Diluted Shares Outstanding		 2.54B 2.53B 2.53B 2.53B 2.53B 2.53B 2.53B 2.51B 2.50B 2.48B 2.47B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 2.54B 2.53B 2.53B 2.53B 2.53B 2.53B 2.53B 2.51B 2.50B 2.48B 2.47B
Normalized Net Operating Profit after Tax (NOPAT)		 -3,508 4,963 -1,198 4,843 5,572 3,079 3,905 5,114 4,918 5,623 3,521
Normalized NOPAT Margin		 -23.33% 31.09% -8.19% 30.70% 34.58% 18.49% 24.99% 32.93% 31.11% 32.55% 21.47%
Pre Tax Income Margin		 -35.48% 35.21% -13.98% 35.94% 37.28% 24.55% 26.69% 38.01% 31.63% 39.04% 20.85%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 231.67% 158.94% 1,974.80% 325.23% 55.58% 63.64% 45.76% 45.50% 48.92% 42.58% 44.77%
Augmented Payout Ratio		 247.26% 179.57% 2,331.83% 382.10% 64.54% 73.59% 53.38% 58.95% 69.88% 65.27% 72.61%

Financials Breakdown Chart

Key Financial Trends

Below are the top takeaways for Merck & Co., Inc. (MRK) drawn from the last four years of quarterly statements, focusing on the latest Q4 2025 data and the four-year trend in income statements, cash flows, and balance sheets.

  • Revenue growth in Q4 2025 versus prior year. Operating revenue rose to $16.40B in Q4 2025 from $15.64B in Q4 2024, indicating ongoing demand and a stronger year-over-year top line.
  • Strong quarterly profitability in Q3 2025. Q3 2025 net income was about $5.79B with diluted earnings per share (EPS) of $2.32, showcasing solid earnings power during the middle of 2025.
  • Consistent positive operating cash flow in 2025, peaking in Q3. Net cash from continuing operating activities reached about $7.82B in Q3 2025, with positive cash flow also seen in Q1 and Q2 2025, supporting liquidity despite quarterly fluctuations.
  • Significant acquisitions in Q4 2025. Acquisitions totaled about $10.04B, reflecting an aggressive growth push, which increases goodwill/intangible assets and balance-sheet complexity.
  • Ongoing investments in R&D and SG&A in Q4 2025. R&D expense was $3.89B and SG&A expense was $2.90B, indicating continued investment in pipeline development and commercial activities, which may pressure near-term margins.
  • Rising leverage signals balance-sheet risk. Long-term debt around $39.97B (Q3 2025) and total liabilities near $77.64B, implying higher leverage that may affect risk/return profiles going forward.
  • Q4 2025 net income declined vs. prior quarters. Net income attributable to common shareholders was about $2.96B in Q4 2025, substantially below Q3 2025’s $5.79B, indicating quarter-specific headwinds or higher spending.
  • Per-share metrics show pressure in Q4 2025. Basic EPS around $1.21 and diluted EPS around $1.19 in Q4 2025, signaling margin pressure at the quarter level despite higher revenue.
  • Significant cash outflows from investing activities in Q4 2025. Net cash from investing activities was about -$11.20B, driven by acquisitions and other investments, weighing on near-term liquidity.
  • Near-term cash balance declined in Q4 2025. Net Change in Cash and Equivalents was about -$3.58B in Q4 2025, reflecting the impact of large investing outflows despite positive operating cash flow earlier in the year.
05/06/26 10:37 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Merck & Co., Inc.'s Financials

When does Merck & Co., Inc.'s fiscal year end?

According to the most recent income statement we have on file, Merck & Co., Inc.'s financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Merck & Co., Inc.'s net income changed over the last 10 years?

Merck & Co., Inc.'s net income appears to be on an upward trend, with a most recent value of $18.26 billion in 2025, rising from $4.46 billion in 2015. The previous period was $17.13 billion in 2024. View Merck & Co., Inc.'s forecast to see where analysts expect Merck & Co., Inc. to go next.

What is Merck & Co., Inc.'s operating income?
Merck & Co., Inc.'s total operating income in 2025 was $21.22 billion, based on the following breakdown:
  • Total Gross Profit: $48.63 billion
  • Total Operating Expenses: $27.41 billion
How has Merck & Co., Inc.'s revenue changed over the last 10 years?

Over the last 10 years, Merck & Co., Inc.'s total revenue changed from $39.50 billion in 2015 to $65.01 billion in 2025, a change of 64.6%.

How much debt does Merck & Co., Inc. have?

Merck & Co., Inc.'s total liabilities were at $84.20 billion at the end of 2025, a 19.0% increase from 2024, and a 48.0% increase since 2015.

How much cash does Merck & Co., Inc. have?

In the past 10 years, Merck & Co., Inc.'s cash and equivalents has ranged from $6.09 billion in 2017 to $14.57 billion in 2025, and is currently $14.57 billion as of their latest financial filing in 2025.

How has Merck & Co., Inc.'s book value per share changed over the last 10 years?

Over the last 10 years, Merck & Co., Inc.'s book value per share changed from 15.99 in 2015 to 21.19 in 2025, a change of 32.5%.


Related Companies

Financial statements for NYSE:MRK last updated on 2/27/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Military ‘Dark Energy’ to Power AI
When it was put inside U.S. tanks, they moved almost silently and produced no smoke. Now, Elon Musk is using t...
Altimetry | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Gold surged 600 dollars last time this indicator peaked
The Buffett Indicator has predicted every major gold bull run this century - 2000, 2008, and 2020, when gold s...
Porter & Company | Sponsoredtc pixel